LncRNA MEG3 activates CDH2 expression by recruitment of EP300 in valproic acid-induced autism spectrum disorder

Neurosci Lett. 2022 Jul 13:783:136726. doi: 10.1016/j.neulet.2022.136726. Epub 2022 Jun 11.

Abstract

LncRNAs partake in the biological processes contributing to development of autism spectrum disorder (ASD). The aim of the present study is to investigate the effects of lncRNA maternally expressed gene 3 (MEG3) on viability and apoptosis of hippocampal neurons from ASD rats. Rats with ASD were induced using valproic acid (VPA) with normal saline (NS) as control. We performed microarray analysis on hippocampal tissues of NS rats and ASD rats to screen the differentially expressed lncRNAs. MEG3 loss in rats alleviated the impairment of learning and memory abilities induced by VPA, and promoted neuronal viability and inhibited apoptosis. MEG3 could recruit the transcription factor E1A binding protein p300 (EP300) in the nucleus and promote the cadherin 2 (CDH2) expression. CDH2 depletion in rats ameliorated the impairment of learning and memory capacities in ASD rats. After upregulation of CDH2 in neurons with sh-MEG3, we found diminished viability and increased apoptosis in hippocampal neurons of ASD rats. Taken together, MEG3 supports activation of CDH2 via EP300, thus repressing the viability of hippocampal neurons. Therefore, MEG3 upregulation may be partially responsible for the pathogenesis of ASD.

Keywords: Autism spectrum disorder; CDH2; EP300; Hippocampal neurons; Long non-coding RNA MEG3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Autism Spectrum Disorder* / metabolism
  • Cadherins / metabolism
  • E1A-Associated p300 Protein / metabolism
  • Hippocampus / metabolism
  • RNA, Long Noncoding* / metabolism
  • Rats
  • Valproic Acid / pharmacology

Substances

  • Cadherins
  • RNA, Long Noncoding
  • Valproic Acid
  • E1A-Associated p300 Protein
  • Ep300 protein, rat